Brief: Dermapharm H1 Adjusted Group EBITDA Margin At 28.9%
Aug 16 (Reuters) - DERMAPHARM HOLDING SE DMPG.DE :
* BOARD OF MANAGEMENT CONFIRMS OUTLOOK FOR FULL YEAR 2023
* ADJUSTED GROUP EBITDA MARGIN AT A PLEASING 28.9%
Source text for Eikon: ID:nEQ6rvzPNa
Further company coverage: DMPG.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit